Home Stock

Stock Research: Hanmi Pharmaceutical

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Hanmi Pharmaceutical

KSC:128940 KR7128940004
21
  • Value
    16
  • Growth
    77
  • Safety
    Safety
    34
  • Combined
    27
  • Sentiment
    44
  • 360° View
    360° View
    21
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Hanmi Pharm Co Ltd manufactures and sells pharmaceuticals. It operates in the pharmaceuticals and materials processing industries, and exports its products. In the last fiscal year, the company had a market cap of $2,625 million, profits of $553 million, and revenue of $1,013 million. There is no data for the number of employees.

more

ANALYSIS: With an Obermatt 360° View of 21 (better than 21% compared with alternatives), overall professional sentiment and financial characteristics for the stock Hanmi Pharmaceutical are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Hanmi Pharmaceutical. The consolidated Growth Rank has a good rank of 77, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 77% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 16 means that the share price of Hanmi Pharmaceutical is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 84% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 34, which means that the company has a riskier financing structure than 66% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 44, indicating professional investors are more pessimistic about the stock than for 56% of alternative investment opportunities. ...read more

more
Strongest Rank Opinions Change
Weakest Rank Stock Returns
Country South Korea
Industry Pharmaceuticals
Size Medium
Website hanmi.co.kr
Index
KOSPI
Hanmi Pharmaceutical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 23-Jun-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
16 16 14 15
Growth
77 72 91 91
Safety
Safety
34 10 10 1
Sentiment
44 72 96 39
360° View
360° View
21 10 49 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
59 81 67 76
Opinions Change
8 32 75 42
Pro Holdings
n/a 70 74 12
Market Pulse
63 63 72 56
Sentiment
44 72 96 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
16 16 14 15
Growth
77 72 91 91
Safety Safety
34 10 10 1
Combined
27 1 27 18
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
19 28 30 39
Price vs. Earnings (P/E)
24 30 26 14
Price vs. Book (P/B)
13 19 12 14
Dividend Yield
67 20 22 17
Value
16 16 14 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
37 61 61 52
Profit Growth
83 56 85 100
Capital Growth
36 90 75 88
Stock Returns
95 28 63 27
Growth
77 72 91 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
56 23 9 2
Refinancing
14 14 9 5
Liquidity
70 75 28 16
Safety Safety
34 10 10 1

Similar Stocks

Discover high‑ranked alternatives to Hanmi Pharmaceutical and broaden your portfolio horizons.

Hyundai Home Shopping Network

KSC:057050
Country: South Korea
Industry: Internet Retail
Size: Medium
Full Stock Analysis

Youngone

KSC:111770
Country: South Korea
Industry: Apparel, Accessories, Luxury
Size: Medium
Full Stock Analysis

Nippon Shinyaku

TYO:4516
Country: Japan
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

SL

KSC:005850
Country: South Korea
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The only positive is high growth. The stock is expensive (low Value Rank), risky to finance, and carries critical professional sentiment. This is a risky proposition. Avoid unless you have exceptional conviction that the growth alone will overcome the price and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews